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ABSTRACT: The solid-state properties of novel complexes of -cyclodextrin and two different solid forms of norfloxacin were investigated
at the molecular level, in an attempt to obtain promising candidates for the preparation of alternative matrices used in pharmaceutical
oral formulations. In order to evaluate the physical properties inherited from the different polymorphs, these supramolecular systems
were characterized using a variety of spectroscopic techniques including natural-abundance 13C cross-polarization magic-angle-spinning
(CP-MAS) nuclear magnetic resonance (NMR), powder X-ray diffraction, and Fourier transform infrared spectroscopy. The intrinsic proton
spin-lattice relaxation times detected in 13C CP-MAS NMR spectra are used to confirm and distinguish the complex formation, as well as
to provide better insights into the molecular fragments that are involved in the interaction with -cyclodextrin. C© 2013 Wiley Periodicals,
Inc. and the American Pharmacists Association J Pharm Sci 102:3717–3724, 2013
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INTRODUCTION
Multicomponent pharmaceutical solids, in crystalline or amor-
phous forms, are usually developed to improve the pharmaceu-
tical profile of a single organic molecule in terms of solubil-
ity, physicochemical stability, bioavailability, and organoleptic
properties.1,2 A better understanding of the solid-state interac-
tions in these solids can allow for the rational design of active
pharmaceutical ingredients (API). Additionally, polymorphism,
the ability of a molecule to exist in several different conforma-
tions, affects the chemical and physical properties of an API
including the solubility, bioavailability, and stability,3,4 which
have a significant impact on pharmaceutical industry.
Norfloxacin (NOR; Figure 1) is a synthetic broad antibacte-
rial fluoroquinolone that has been widely used in the treatment
of various infectious diseases, such as gonorrhea, prostate, and
urinary tract infections.5 NOR is very slightly soluble in wa-
ter, which is associated with the poor biological availability, as
only 35%–45% of the orally administered drug is absorbed.6–8
NOR exists in several solid forms: three anhydrous polymorphs
(forms A, B, and C), an amorphous form, a methanol solvate,
several hydrate forms, and also salts and cocrystals.9–11
An approach to increase the water solubility, stability, and
bioavailability of drugs is the formation of complexes with
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modified starches as cyclodextrins (CDs), calix[n]arenes, and
maltodextrins.12–16 Particularly, solid drug−CD inclusion com-
plexes present challenges for structural analysis. The solid pow-
ders can be relatively complex, and multiple amorphous and
crystalline phases can be present, including a combination of
drug phases.17,18 In previous reports, CDs have been used to
increase the solubility, the dissolution rate, and/or the bioavail-
ability of NOR.19–21 However, these studies have not considered
the different solid forms of this API.
Several solid-state techniques are commonly used to char-
acterize pharmaceutical multicomponent systems and to iden-
tify polymorphism.22 To obtain a complete physical character-
ization of a product, optical microscopy, thermal analysis, and
solid-state spectroscopic techniques are implemented, in partic-
ular powder X-ray diffraction (PXRD) and solid-state nuclear
magnetic resonance (ssNMR) spectroscopy.23 Among these tech-
niques, ssNMR, specifically 13C cross-polarization magic-angle
spinning (CP-MAS), has proven to be a powerful analytical
technique in which heterogeneous samples can be investigated,
and amorphous content provides no significant barrier to such
studies.24,25 However, less efforts have been made to measure
1H spin-lattice relaxation times through 13C spectra, which can
be very useful in studying the molecular dynamics in complex
compounds, and to separate different contributions in mix-
tures and multicomponents products, using pseudo-2D mea-
surements or in the inverse Laplace transform version.17,26–28
Having in mind the improvement on the solubility and dis-
solution behavior of NOR and to select a proper polymorph
for its pharmaceutical use, the aim of the present work was
to synthesize and characterize novel supramolecular systems
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of various solid forms of NOR with $-cyclodextrin ($CD). The
polymorphs of NOR, their physical mixtures with $CD, and
the corresponding NOR–$CD complexes were investigated us-
ing a variety of spectroscopic techniques: ssNMR, PXRD, and
Fourier transform infrared (FT-IR) spectroscopy. Additionally,
the measurement of the proton 1H spin-lattice relaxation times
(1H T1) using 1H spin-inversion recovery experiments detected
in 13C ramped-amplitude (Ramp)-CP-MAS spectra has enabled
us to gain better insights into the complex formation, as well
as into the interactions among their individual components at
the molecular level.
EXPERIMENTAL SECTION
Chemicals and Reagents
Norfloxacin was provided by Parafarm (Buenos Aires, Ar-
gentina) and $CD (MW = 1135) was kindly supplied by Fer-
romet agent (Buenos Aires, Argentina) of Roquette (France).
All other chemicals were of analytical grade.
Obtaining the Polymorphic Forms of NOR
The two solid forms of NOR were prepared as reported by Bar-
bas and coworkers.9–11 NOR C was produced by suspending
NOR (marketed as form A) in acetone, heated to reflux, and
then allowed to cool slowly to room temperature. In an attempt
to produce NOR B, NOR was dissolved in refluxing isopropanol
and then cooled slowly to room temperature. However, the prod-
uct obtained trying to reproduce the experimental conditions
was a different solid form; thus, herein we denote this form as
NOR BI.
Solid Samples Preparation
Solid-state systems of NOR BI or C, in equimolar ratio with the
$CD were prepared as follows:
Kneading Method.
The systems NOR BI:$CD (KN [kneading method] BI) and NOR
C:$CD (KN C) were prepared by accurately weighing appropri-
ate amounts of $CD and then transferring them to a mortar. An
acetone–water (50:50, v/v) mixture was added to the $CD pow-
der and the resultant slurry was kneaded for about 10 min. For
each system, the corresponding solid form of NOR was added in
small portions with the simultaneous addition of solvent in or-
der to maintain a suitable consistency. This slurry was kneaded
thoroughly for about 45 min, and the resultant paste was dried
in vacuum at 40◦C for 48 h, and protected from light.
Physical Mixture.
Physical binary mixtures of NOR BI:$CD (PM BI) and NOR
C:$CD (PM C) were prepared by simply blending uniformly the
corresponding components with a mortar and pestle.
ssNMR Spectroscopy
All ssNMR experiments were performed at 11.75 T on a Agilent/
Varian VNMRJ 500 MHz NMR spectrometer operating at a
resonance frequency of 125.6 MHz for 13C and 499.44 MHz for
1H, and using a 3.2-mm triple-resonance MAS probe. High-
resolution solid-state 13C MAS NMR spectra of NOR BI and
NOR C, as well as the systems KN BI, KN C, PM BI, and
PM C, were acquired under 10 kHz MAS conditions at am-
Figure 1. NOR and $CD molecular structures with the carbon num-
bering used in NMR spectra.
bient temperature using a ramped-amplitude Ramp-CP pulse
sequence during an acquisition period of 10 ms with a 2 ms
cross-polarization contact time. A 68-kHz SPINAL6429 pulse
scheme was applied to decouple protons during signal acquisi-
tion. All spectra were recorded with 2000 transients and a recy-
cle delay of 5 s. Carbon-13 NMR chemical shifts were referenced
with respect to Tetramethylsilane at 0 ppm using adamantane
as a secondary external standard.
The 1H T1 were calculated from a series of data collected by
1H spin-inversion recovery experiments detected in 13C Ramp-
CP-MAS, in which a 1H B-pulses followed by an inversion
recovery delay Jwere introduced prior to the Ramp-CP pulse se-
quence and SPINAL64 decoupling scheme. A 0.2 ms of CP con-
tact time was selected to avoid spin diffusion between protons
in order to obtain information of the nearest carbons. Thirteen
data points with increasing inversion recovery delays (between
0 and 5 s) were recorded for each sample, with a 5-s recycle de-
lay and 500 transients collected under 10 kHz MAS condition.
Powder X-Ray Diffraction
Powder X-ray diffraction patterns were obtained at ambi-
ent temperature using a Bruker D8 Advance diffractometer
(Bruker Corporation/ Bruker AXS, Inc., Madison, WI) operat-
ing at 40 kV and 40 mA with Cu-K" radiation (1.5406 A˚). All
samples were packed into the depression of an indented quartz
slide. The powder pattern was collected by scanning 22 from 3◦
to 70◦ with a step size of 0.04◦ at a rate of 1.5 s/step.
Fourier Transform Infrared
The FT-IR spectra were recorded on a Nicolet 5 SXC FT-IR
Spectrophotometer (Madison, Wisconsin). The potassium bro-
mide disks were prepared by compressing the powder.
RESULTS AND DISCUSSION
13C CP-MAS NMR Spectroscopy
The carbon numbering of NOR and $CD molecules is shown in
Figure 1. Figure 2 displays the 13C CP-MAS spectra of $CD,
NOR BI, NOR C, the corresponding physical mixtures (PM BI,
PM C), and complexes (KN BI, KN C). As shown in their individ-
ual spectra, both NOR and $CD exhibit different and separate
ranges of 13C chemical shifts. The 13C NMR resonances of NOR
lie in the 100 –180 ppm region and below 60 ppm, whereas
those of $CD lie between 50 and 110 ppm. $CD presents sharp
resonances typical of a crystalline system.16
The 13C CP-MAS NMR spectrum of NOR C matches well
with that previously reported11 ; however, the 13C CP-MAS
spectrum for NOR BI differs from the reported spectrum for
NOR B.9,10 A number of NOR BI resonances appear at the same
shift positions reported for the form B but with double number
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Figure 2. 13C cross-polarization magic-angle-spinning spectra of $CD, NOR BI and C, PM BI and C, and the complexes KN BI and C.
Numbering for assignments corresponds to Figure 1. Only signals that are visible have been assigned in the PMs and KNs spectra.
of peaks; the most noticeable is the four peaks corresponding
to carbons 4 and 9. Moreover, the spectrum clearly shows that
compound NOR BI is not a mixture of NOR B and C, as the
chemical shifts of forms B and C are quite similar. Thus, this
result demonstrates that NOR BI represents a new solid form
different than form B, albeit crystallized from the same solvent.
Comparing the KN BI with PM BI spectra, it is possible to see
several differences in all the signals, indicating that complex
KN BI is a completely new solid form. For example, signals
corresponding to carbons 1′-6′ of $CD have merged into single
and broad peak in the range of 55 –110 ppm; signals corre-
sponding to NOR BI have shifted in position and are broadened
as well. In particular, the 40–50-ppm region corresponding to
the piperazine ring (",$) that in PM BI maintains the NOR BI
shape but has a completely different feature in the complex.
The changes in the signals between 165 and 180 ppm and the
signals at 18 ppm (carbon 11), which turned into a doublet, are
also remarkable. By comparing the KN C with PM C spectra,
differences in the signals belonging to $CD region (between 87
and 57 ppm) were observed, which became broader and the
sharp peaks disappeared, for example, for carbons 1′ and 4′.
There are also shifts to higher ppm for the group of signals
between 55 and 35 ppm. The signal corresponding to carbon 11
(at 16 ppm) appears as a doublet like in KN BI. KN BI and KN
C can be easily distinguished by observing the signals at 85 and
64 ppm in the KN BI spectrum that are not present in that of
KN C. Note that there are no residues of the precursors in the
complexes KNs, as every part of the spectra has changed.
In the PMs, most of the signals appear at the same chem-
ical shift positions as those in the pure compounds, although
each spectrum are not the exact addition of the corresponding
polymorph of NOR and $CD spectra. For example, the group
of signals in the region between 40 and 50 ppm (carbons 10,
", $) has the same feature than the pure NOR polymorph, and
the resonances appearing in the region corresponding to $CD
are broadened with some remaining sharp peaks. These facts
indicate that both compounds (NOR and $CD) are not strongly
interacting in the physical mixture. PM BI and PM C are dif-
ferent compounds, as confirmed by the signals belonging to
carbons 10 and ", $ of NOR and 4′ and 6′ of $CD.
Proton T1 Relaxation Analysis
To obtain additional information on the interaction between
the pure components in the complexes, 1H T1 were measured
through the carbon spectra. Spin-lattice relaxation times of the
different protons in a sample are averaged to a single value
by the spin diffusion process. This average is usually complete
when protons belong to the same phase domain, whereas re-
laxation times of different domains in heterogeneous samples
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Figure 3. 13C cross-polarization magic-angle-spinning spectra of KN BI and PM BI with 200 :s of contact time at different recovery time delays
showing the integration regions (I, II, and III) used to calculate spin-lattice relaxation times (T1) of protons.
can be averaged or not, depending on the dimensions of the
different domains and connections between spins.26
To determine 1H T1, signals belonging to different carbon re-
gions in each 13C CP-MAS spectrum were integrated to deter-
mine the magnetization as a function of the delay time. Then,
the behavior of 1H magnetization as a function of the recovery
time was fitted by using one relaxation time in all the cases. It
is important to note that with 200 :s of contact time only some
signals are visible in the carbon spectra. This short contact time
is used to avoid proton spin diffusion during cross-polarization.
Thus, the contribution and behavior of protons in very close
proximity to specific carbons were obtained.
Figure 3 shows the three different regions that were consid-
ered for integration in all the compounds: region I (55 –40 ppm),
which is characteristic of carbon 10 and (", $) of NOR, region
II (around 87 –56 ppm), containing signals of carbons (4′, 2′,
3′, 5′, 6′) characteristics to $CD, and region III (around 100 –
110 ppm), where NOR and $CD have signals (8 and 1′). The
values of T1 calculated for these regions are given in Table 1.
In both PMs, the two corresponding components maintain re-
laxation time values quite similar to those measured for their
pure samples: 1.82 s for NOR BI, 1.91 s for NOR C, and 0.46 s for
$CD. Remarkably, all the KN BI regions present different val-
ues in comparison with PM BI, confirming that KN BI is a new
solid form, homogeneous and different from its precursors (see
Table 1). Indeed, Figure 3 shows that regions I and II belong-
ing to PM BI present null signals at 1.25 and 0.2 s, respectively,
whereas in KN B, all the regions recover their positive signals
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Table 1. Values of Spin-Lattice Relaxation Times (T1) of Protons
Corresponding to Each Region of the Carbon Spectra (I, II, or III) in
All the Compounds
1H-T1 (s)
Region I Region II Region III
(55–36 ppm) (87–56 ppm) (110–100 ppm)
NOR BI 1.82 – 1.64
PM BI 1.85 0.46 0.60
KN BI 1.55 1.45 1.38
NOR C 1.91 – 1.71
PM C 1.80 0.46 0.64
KN C 1.0 0.50 0.62
Errors are within 5%.
at around 0.8 s. Regions inside KN BI have slightly different
values and the longer one corresponds to region I, which corre-
sponds to the piperazine ring of NOR.
In the case of KN C, not all the regions have homogenous
T1 values. The most distinguishable is region I, having a value
of 1.80 s in PM C that becomes 1.0 s in KN C (see Table 1).
Instead, regions II and III have similar values to that of the
physical mixture. Although spectroscopically we can see that
PM C and KN C are different, from the point of view of the
relaxation behavior there is evidence that KN C has a solid
form closer to the physical mixture. The absence of pure drug
is also evident from the relaxation time measurements. Again,
as occurs in the case of KN BI, region I has the largest value
of T1.
This different relaxation time values corresponding to re-
gion I in both complexes may be attributed to an incomplete
spin diffusion averaging, indicating that this value belongs to
a different domain that may be involved in an inclusion pro-
cess. This behavior is in agreement with the results reported
by Torres-Labandeira et al.,20 who reported 1H-NMR studies
suggesting that the piperazine group of NOR is bound inside
the $CD cavity.
Powder X-Ray Diffraction
The powder X-ray diffractograms for NOR BI and C and their
corresponding PMs and KNs are shown in Figure 4.
The PXRD pattern for NOR C shows excellent agreement
with that previously reported in the literature.11 However, the
PXRD pattern for NOR BI displays reflections distinctly differ-
ent from those reported previously for NOR B.9,10 NOR C and
NOR BI are clearly distinguishable by the reflections present in
NOR C (22= 9.2◦, 16.1◦, 16.6◦, 17.1◦, and 18.8◦), but absent in
NOR BI. Hence, the solid form NOR BI obtained is not a mixture
of forms C and B, as supported by 13C CP-MAS. Additionally,
the PXRD data of NOR BI show reflections at 22= 10.7◦, 11.4◦,
12.6◦, and 13.4◦, which are in agreement with previous hydrates
reported in for NOR A.30 Then, in order to complete the char-
acterization of this solid, we performed a thermogravimetric
analysis (TGA) experiment (Figure 1S in Supporting Informa-
tion). Our TGA results together with PXRD reveal that the new
solid form obtained corresponds to a hydrate of the polymorph
B, which is reported for the first time herein. Therefore, the
13C NMR, PXRD, and TGA data suggest that it is difficult to
reproduce the experimental conditions for obtaining NOR B.
Figure 4. Powder X-ray diffraction patterns of $CD, NOR BI, NOR C, PM BI and C, and KN BI and C.
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Figure 5. FT-IR spectra of NOR BI and NOR C.
In the PXRD pattern for PM BI, characteristic reflections of
NOR BI at 22 = 10.7◦ and 13.3◦ are observable. The PXRD
pattern for PM C shows representative reflections of NOR C at
22 = 16.1◦, 18.8◦, and 22.4◦, and also characteristic reflections
of $CD at 22 = 12.8◦ and 13.5◦. Additionally, the PXRD patterns
for PM C and PM BI are distinct, showing that these physical
mixtures are not the same.
It is possible to distinguish between the PMs and KNs by
examining the PXRD patterns, which show some reflections in
each PM diffractogram that are not present in the correspond-
ing KN powder pattern. Furthermore, the PXRD patterns for
KN BI and KN C clearly demonstrate that these are different
materials. In the PXRD pattern for KN BI, there are reflections
present at 22 = 23.1◦ and 21.0◦, which are absent in the PXRD
pattern for KN C. These results show that the complexes KN BI
and KN C are distinct crystalline solids having different PXRD
patterns from both NOR BI and NOR C and the two physical
mixtures, PM C and PM BI.
Fourier Transform Infrared
Segments of the FT-IR spectra of NOR BI and C, $CD, their
corresponding PMs, and KNs systems are shown in Figures 5
and 6.
Figure 6. FT-IR spectra of $CD, NOR BI, PM BI, KN BI, NOR C, PM C, and KN C.
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Table 2. Infrared Bands Assignment
Wavenumber (cm−1)
Assignment NOR BI NOR C
N–H and O–H stretch 3380 3434
Olefinic and aromatic C–H stretch 3042
Asymmetric C–H stretch in methyl
and methylene of ethyl and
piperazine groups
2972 2915
Symmetric C–H stretch in methyl
and ethylene of ethyl and
piperazine groups
2852 2769
Hydrogen bonded O–H stretch 2550
Pyridone C=O stretch 1625 1621
N–H deformation 1580 1582
Quinoline ring C–C and C–N stretch 1489 1482
Aromatic C–H deformation 836, 821 827
Rocking vibrations of the alkyl chains 740 737
NOR BI and NOR C were readily distinguished by the differ-
ences in their FT-IR spectra (Figure 5, Table 2). It is important
to note that the bands in the region 3500 –2500 cm−1, showing
marked differences between both solid forms, have not been
previously reported.9–11 The band between 3600 and 3100 cm−1
for NOR BI, which is more intense than that for NOR C, can be
attributed to the overlapping bands of H2O with amino groups.
As shown in Figure 6, in the FT-IR spectrum of KN BI,
the band assigned to the pyridone C=O stretch (1625 cm−1)
was shifted to the higher frequency of 1632 cm−1. In addition,
the bands at 1580 and 1264 cm−1 were shifted to 1578 and
1269 cm−1, respectively. Also, the band corresponding to the
rocking vibrations of the alkyl chains was shifted to 736 cm−1.
For KN C (Figure 6), the bands corresponding to the pyridone
C=O stretch and to the vibrations of the alkyl chains were
shifted to 1628 and 735 cm−1, respectively. In contrast, the spec-
tra of PM BI and PM C corresponded simply to the superposi-
tion of the FT-IR spectra of the single components. From these
events, we suggest that the pyridone ring of each polymorph
interacted with the $CD in the solid state. Similar results have
been reported for NOR/CD complexes, suggesting that the car-
boxylic portion of the NOR is predominantly included within
the apolar cavity of $CD.31
CONCLUSIONS
In this work, we have confirmed that solid-state NMR, comple-
mented with other spectroscopic techniques, is a powerful tool
for the challenging characterization of different solid forms of
an API and its multicomponent pharmaceutical systems with
CD.
In particular, we have developed and characterized new
supramolecular complexes of two different solid forms of NOR
and $CD. Clear evidence of the complexation was observed
by variety of spectroscopic techniques (13C CP-MAS ssNMR,
PXRD, and FT-IR) and 1H T1 measurements.
The 1H relaxation times confirmed that the complexes are
homogeneous samples with absence of free-drug unbound to
$CD, and moreover, that they are different to the physical mix-
tures. A different 1H T1 for the piperazine ring and the shifts
in the FT-IR spectra of the pyridone ring provided evidence
of strong interactions between NOR molecules and $CD. Addi-
tionally, it was interesting to note that the solid form denoted
as NOR BI (obtained by reproducing the procedure reported
for NOR B) represents a new solid form different from the
other reported ones. Our results suggest that the new solid form
corresponds to a hydrate of NOR B, not reported in any previ-
ous publications. Then, the structural characterization of this
new solid form has shown the difficulty in reproducing the ex-
perimental conditions for crystallizing NOR B.
We believe that our strategy, based on the interaction be-
tween NOR and CD, provides novel complexes that are po-
tential alternatives to optimize insufficient features of drug
molecule, such as solubility, stability, or toxic effects. These
complexes are valid tools for the preparation of pharmaceu-
tical dosage products, and represent an option to promote the
pharmaceutical design for the improvement of physicochemical
properties.
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